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UK data 89.35 83 84.14 86.18
SEER data 75.3 72.4 73.2 73.8
UK data 73.4 66.83 69.04 70.12
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ABSTRACTSMethods: All patients (n¼101) undergoing breast surgery in November
2012 were prospectively audited. The dose, timing and appropriateness
of LMWH administration were reviewed and compared to the UHL
protocol.
Results: 100/101 patients received LMWH with 95% of patients receiving
2500 units and 94% receiving LMWH pre-operatively. Furthermore 7% of
patients received LMWH despite it not being indicated.
Conclusions: The current practice is not standardised and a proportion
of patients (7%) were over-treated. There are no published RCTs con-
cerning the appropriate timing or dose of LMWH for general surgery and
none concerning the use of VTE prophylaxis for breast surgery specif-
ically. The incidence of VTEs or haematomas/haemorrhage is extremely
low so large scale trials would be required to provide statisticially sig-
niﬁcant evidence.
0700: CLINIC LETTERS; HOW WELL ARE WE COMMUNICATING?
Yoon Jung Lee, Jayne Robinson, Alison Waghorn. Royal Liverpool University
Hospital, Liverpool, Mersey, UK.
Introduction: Clinic letters are important for communication between
healthcare professionals and patients. Department of Health guideline
indicates that all patients should receive their clinic letters, but with the
content adjusted. This audit aimed to assess the compliance to the DoH
guideline and highlight the variations between the letters.
Method: Therewere 18 clinics from six consultants eachweek. Clinic letters
for ten randomly selected patients from each clinic bewteen 09/05/12 and
18/05/12 were obtained, including additional referrals. In total, 141 clinic
letters were analysed for primary and additional recipients, and contents.
Results: 51% of the clinic letters were sent to the patients, 26% of which
were achieved by two consultants who primarily addressed to the patients.
Only one letter stated the patient opting out. 46% were in a mix of freeform
and pro-forma while the rest were in freeform. Collectively, 90% of the
letters included clinical presentation with 82% indicating the working
diagnosis but there was a variation between the consultants and clinics.
Conclusion: Currently, the department is not fully complying with the
DoH guideline and should endeavour to improve this. A uniform pro-forma
with additional freeform is also recommended to ensure all important
clinical information is included.
0738: LIPOMODELLING GUIDELINE AUDIT
Philippa Jefferson, Charlotte Ives, Douglas Ferguson. Royal Devon and Exeter
Hospital, Exeter, UK.
Aim: To audit previous practice against the ABS breast lipomodelling
guidelines.
Methods: A retrospective case note review October 2007 until December
2012
Results: 104 procedures, 72 female, 3 male, age 19 to 72 years. 85.33%
following breast cancer surgery. Guidelines suggest patients be:-
Discussed at multidisciplinary meeting with up to date imaging: 7.81% had
MDT recorded within a year of lipomodelling. Five had imaging within a
year of surgery. Non-smokers: 18.66% were smokers at time of procedure.
At least 12 months from radiotherapy: of 38 patients who had radio-
therapy (50.66%) ﬁve (13.16%) had lipomodelling within a year. Followed
up early, 3 months & 1 year: No clear protocol for follow-up identiﬁed.
Given donor site adrenaline inﬁltration: Adrenaline documented in 72%
cases. Guidelines suggest complication rates of: Fat necrosis between 3-
15%: 4.8% in the study; Infections between 0.6-1.1%: 0.96% in the study; No
recurrent breast cancer in patients undergoing lipomodelling was
identiﬁed.
Conclusion: Lipomodelling appears safe with acceptable complication
rates. The ABS/BAPRAS guidelines on safe practice for lipomodelling were
available after most cases had been performed. Breast cancer cases should
be discussed in MDT prior to lipoﬁlling.
0754: THE ROLE OF AXILLARY CLEARANCE FOLLOWING SENTINEL
LYMPH NODE BIOPSY IN BREAST CONSERVING SURGERY
James Warbrick-Smith, Ajay Sahu. North Bristol NHS Trust, Bristol, UK.
Introduction: Current standards of care for clinically node-negative breast
cancer patients undergoing breast conserving surgery dictate that these
women are offered sentinel lymph node biopsy (SLNB) which, if positive, is
followed by axillary lymph node clearance (ALNC). Recent trial evidencefrom Z-0011 and NSABP-B32 suggests that progression to ALNC for some of
these women may be unnecessary. We audited the results of a single
surgeon over 1 year to establish support for this paradigm shift.
Methods: We retrospectively audited pathology reports for women un-
dergoing breast conserving surgery and SLNB followed by ALNC during
2010 at our Trust.
Results: 100women underwent SLNB during the study period, of which 17
were positive and proceeded to ALNC. There was one case of false negative
SLNB. Of the true positive SLNB patients, ALNC revealed nil further
involved nodes in 7 cases (41%), and only 1 further involved node in 4 cases
(24%). In only three cases was level III disease encountered.
Conclusions: In 41% of our cases SLNB itself was effectively therapeutic for
local disease control, and thus ALNC may have been un-necessary. Further
work is required to identify which women may be able to avoid comple-
tion lymphadenectomy.0797: INTRAOPERATIVE INJECTION OF RADIOISOTOPE IS EFFECTIVE IN
THE DETECTION OF SENTINEL LYMPH NODES IN BREAST CANCER
Jeremy Lynch, Ramesh Chandrabhan-Singh, Richard Sainsbury. St Mary's
Hospital, Isle of Wight, UK.
Introduction: The intraoperative identiﬁcation of the sentinel lymph node
(SLN) in breast cancer surgery has been critical to reducing the morbidity
of this operation. The gold standard involves the combined subareolar
injection of blue dye and radioisotope. This is conventionally given before
induction of anaesthesia whilst the patient is awake, which can be painful
and cause anxiety. We hypothesized the injection can be delivered after
induction of anaesthesia without reducing its reliability for identiﬁcation
of the SLN.
Methods: Patients with breast cancer undergoing SLN biopsy from
September 2011 e September 2012 underwent intradermal subareolar
injection of Tc-99 radioiosotope and blue dye immediately after induction
of general anaesthesia.
Results: 70 patients were included with a median age of 64 years. There
was 1 failed localisation. Themean SLNs retrieved per patient was 1.61, and
the mean time to localisation was 21.6 minutes. The negative predictive
was 91.8% and the speciﬁcity was 96.6%.
Conclusion: Injection of radioisotope and blue dye after induction of
anaesthesia reduces pain and still allows reliable identiﬁcation of the SLN.0857: RANDOM FORESTS: THE NEW GENERATION OF MACHINE
LEARNING ALGORITHMS TO PREDICT SURVIVAL IN BREAST CANCER
Asmaa Al-Allak, Gianﬁlippo Bertelli, Paul Lewis. Swansea University,
Swansea, UK.
Aims: With the advent of computer technologies new ‘machine learning’
algorithms (ML) have been developed that employ a variety of statistical,
probabilistic and optimisation tools to ‘learn’ and predict outcomes. The
aimof our studywas to apply such an algorithm to predict survival in breast
cancer and compare its performance to traditional statistical methods.
Methods: The Surveillance Epidemiology and End Results (SEER) and a UK
data base from SouthWales were used to generate predictivemodels based
on a number of predictive factors. Random Forests (RF) was selected as the
ML method and logistic regression (LR) as the traditional method. Model
performance was estimated using sensitivity, speciﬁcity, precision and
accuracy.
Results: the table below summarises the resultsConclusions:We have shown that newML algorithms can outperform the
traditional statistical methods that have in the past been used to generate
tools that predict survival. These new methods can offer a viable alterna-
tive to generate more accurate predictive models with the potential of
improving patient outcomes.
